Talk:Enrico Mini

Comments left by AfC reviewers

• Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. HRShami (talk) 04:24, 19 December 2025 (UTC)

Research section

Please add this sentence at the end of the research section: He has been named in the Stanford/Elsevier World’'s Top 2% Scientists list 2024 and 2025. HRShami (talk) 09:11, 2 January 2026 (UTC)

 Done, and I reworded "Stanford/Elsevier World’'s Top 2% Scientists" to "Stanford University-Elsevier World’'s Top 2% Scientists List". MosquitoDestroyer (talk | mosquitoes destroyed) 00:06, 7 January 2026 (UTC)

References

Career section

Please add this sentence at the end of the career section: Since 2018, he has been the coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology. HRShami (talk) 09:13, 2 January 2026 (UTC)

 Done, and I reworded "cancer" to "oncological" as that is what the source describes the group as. MosquitoDestroyer (talk | mosquitoes destroyed) 00:03, 7 January 2026 (UTC)

References

Career Section

Please add this line to the career section's second paragraph: In 2014, he was appointed as the director of the Unit of Translational Oncology at Careggi University Hospital and in 1992 was appointed head of the Laboratory of Cancer Pharmacology and Chemotherapy at the University of Florence.

The second part of the sentence above is confirm through the last reference of the paragraph.

Here's the paragraph with the sentence add so that the current paragraph may be replaced with this one in the article: Mini was the chairman of the Cancer Section of the International Society of Chemotherapy from 2007 to 2013. Between 2011 and 2020, he was appointed as director of the Specialty School of Medical Oncology at the University of Florence. In 2014, he was appointed as the director of the Unit of Translational Oncology at Careggi University Hospital and in 1992 was appointed head of the Laboratory of Cancer Pharmacology and Chemotherapy at the University of Florence. He held these positions until his retirement in 2022, after which he continued as the scientific lead of funded research projects. Since 2018, he has been the coordinator of the Oncological Pharmacology Working Group of the Italian Society of Pharmacology. HRShami (talk) 06:17, 9 January 2026 (UTC)

References

Research

I have changed the research section to address the tag placed on it currently.

−

Mini's research contributed to clarifying the mechanisms of [[methotrexate]] (MTX), a chemotherapeutic and immunosuppressive agent that exerts its effects by binding to the [[folic acid]] target [[enzyme]] [[dihydrofolate reductase]] (DHFR), a mechanism widely recognized in cancer therapy.<ref>{{cite thesis |last1=Peng |first1=Lun |title=Sequence-defined carriers for drug and nucleic acid delivery |date=2022 |publisher=Ludwig-Maximilians-Universität München |doi=10.5282/edoc.30409 }}{{pn|date=December 2025}}</ref> whereby methotrexate functions as an [[antifolate]] agent by targeting dihydrofolate reductase (DHFR), which catalyzes the transformation of dihydrofolate (DHF) into [[tetrahydrofolate]] (THF).<ref>{{Cite journal|url=|title=Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo|first1=Robert|last1=Mauritz|first2=Godefridus J.|last2=Peters|journal=Cancer Chemotherapy and Pharmacology|volume=62|issue=6|page=938|date=November 2008|doi=10.1007/s00280-008-0683-0|pmid=18283461 }}</ref><ref>{{Cite journal|title=The extremely halophilic archaeon Haloferax volcanii has two very different dihydrofolate reductases|first1=R.|last1=Ortenberg|first2=O.|last2=Rozenblatt-Rosen|journal=Mol Microbiol|volume=35|issue=6|page=1501|date=March 2000|doi=10.1046/j.1365-2958.2000.01815.x|pmid=10760149 }}</ref> In related research, it was demonstrated that polyglutamylation of methotrexate contributes to its selective cytotoxic effect.<ref>{{Cite journal |title=Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro |first1=I. |last1=Fabre |first2=G. |last2=Fabre |first3=I. D. |last3=Goldman |journal=Cancer Research |volume=44 |issue=8 |date=1984|pages=3190–3195 |pmid=6204743 }}</ref>

+

Mini's research contributed to clarifying the mechanisms of [[methotrexate]] (MTX), an antifolate chemotherapeutic and immunosuppressive agent that exerts its effects by binding to the [[folic acid]] target [[enzyme]] [[dihydrofolate reductase]] (DHFR), a mechanism widely recognized in cancer therapy.<ref>{{cite thesis |last1=Peng |first1=Lun |title=Sequence-defined carriers for drug and nucleic acid delivery |date=2022 |publisher=Ludwig-Maximilians-Universität München |doi=10.5282/edoc.30409 }}{{pn|date=December 2025}}</ref> DHFR catalyzes the transformation of dihydrofolate (DHF) into [[tetrahydrofolate]] (THF).<ref>{{Cite journal|url=|title=Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo|first1=Robert|last1=Mauritz|first2=Godefridus J.|last2=Peters|journal=Cancer Chemotherapy and Pharmacology|volume=62|issue=6|page=938|date=November 2008|doi=10.1007/s00280-008-0683-0|pmid=18283461 }}</ref><ref>{{Cite journal|title=The extremely halophilic archaeon Haloferax volcanii has two very different dihydrofolate reductases|first1=R.|last1=Ortenberg|first2=O.|last2=Rozenblatt-Rosen|journal=Mol Microbiol|volume=35|issue=6|page=1501|date=March 2000|doi=10.1046/j.1365-2958.2000.01815.x|pmid=10760149 }}</ref> In related research, it was demonstrated that polyglutamylation of methotrexate contributes to its selective cytotoxic effect.<ref>{{Cite journal |title=Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro |first1=I. |last1=Fabre |first2=G. |last2=Fabre |first3=I. D. |last3=Goldman |journal=Cancer Research |volume=44 |issue=8 |date=1984|pages=3190–3195 |pmid=6204743 }}</ref>

−

Mini proposed that administering MTX before 5-FU produces synergy, since the polyglutamated MTX can replace 5,10-CH2-THF in the ternary complex.<ref>{{cite journal |last1=Isacoff |first1=William H. |last2=Borud |first2=Katrina |title=Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview |journal=World Journal of Surgery |date=1997 |volume=21 |issue=7 |pages=748–762 |doi=10.1007/S002689900301 |pmid=9276707 }}</ref> He further indicated that alterations in the balance of polyglutamylated MTX forms often lead to the development of drug resistance.<ref>{{cite journal |last1=Szabó |first1=Ildikó |last2=Orbán |first2=Erika |last3=Schlosser |first3=Gitta |last4=Hudecz |first4=Ferenc |last5=Bánóczi |first5=Zoltán |title=Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells |journal=European Journal of Medicinal Chemistry |date=2016 |volume=115 |pages=361–368 |doi=10.1016/j.ejmech.2016.03.034 |pmid=27031212 }}</ref> His studies pointed out that the recognition of [[leucovorin]] as a biomodulator of [[5-fluorouracil]] (5-FU) cytotoxicity in preclinical experiments prompted a surge of phase I and II clinical investigations.<ref>{{Cite journal|title=Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update|first1=Nurul-Syakima|last1=Ab Mutalib|first2=Najwa F.|last2=Md Yusof|first3=Shafina-Nadiawati|last3=Abdul|first4=Rahman|last4=Jamal|journal=Frontiers in Pharmacology|volume=8|issue=|page=2|date=2017|article-number=736 |doi=10.3389/fphar.2017.00736|pmid=29075194 |pmc=5644034 |doi-access=free }}</ref>

+

Mini proposed that administering MTX before [[5-fluorouracil]] (5-FU) produces synergy, since the polyglutamated MTX can replace 5,10-CH2-THF in the ternary complex.<ref>{{cite journal |last1=Isacoff |first1=William H. |last2=Borud |first2=Katrina |title=Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview |journal=World Journal of Surgery |date=1997 |volume=21 |issue=7 |pages=748–762 |doi=10.1007/S002689900301 |pmid=9276707 }}</ref> He further indicated that alterations in the balance of polyglutamylated MTX forms often lead to the development of drug resistance.<ref>{{cite journal |last1=Szabó |first1=Ildikó |last2=Orbán |first2=Erika |last3=Schlosser |first3=Gitta |last4=Hudecz |first4=Ferenc |last5=Bánóczi |first5=Zoltán |title=Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells |journal=European Journal of Medicinal Chemistry |date=2016 |volume=115 |pages=361–368 |doi=10.1016/j.ejmech.2016.03.034 |pmid=27031212 }}</ref> His studies have led to the recognition of [[leucovorin]] as a biomodulator of 5-FU cytotoxicity in preclinical experiments prompting a surge of phase I and II clinical investigations.<ref>{{Cite journal|title=Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update|first1=Nurul-Syakima|last1=Ab Mutalib|first2=Najwa F.|last2=Md Yusof|first3=Shafina-Nadiawati|last3=Abdul|first4=Rahman|last4=Jamal|journal=Frontiers in Pharmacology|volume=8|issue=|page=2|date=2017|article-number=736 |doi=10.3389/fphar.2017.00736|pmid=29075194 |pmc=5644034 |doi-access=free }}</ref>

−

Mini, through his research, highlighted the negative role of P-gp, an [[ABC transporter]] with extensive substrate specificity in anticancer therapy for leukemia and other solid tumors.<ref>{{Cite journal|last1=Vinogradov|first1=Serguei|last2=Wei|first2=Xin|title=Cancer stem cells and drug resistance: the potential of nanomedicine|journal=Nanomedicine (Lond)|volume=7|issue=4|date=2012|pages=597–615 |doi=10.2217/nnm.12.22|pmid=22471722|pmc=3376090}}</ref> He then strategically modified anticancer drugs to reduce P-gp-mediated efflux<ref>{{Cite journal|title=Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment|first1=Deepali|last1=Waghray|first2=Qinghai|last2=Zhang|journal=Journal of Medicinal Chemistry|volume=61|issue=12|pages=5108–5121|date=2018|doi=10.1021/acs.jmedchem.7b01457|pmid=29251920 |pmc=6281405 }}</ref> and underlined the need for creating drugs that are non-P-gp substrates to counter cancer resistance hindrances.<ref>{{cite journal |last1=Van Vuuren |first1=Rustelle Janse |last2=Visagie |first2=Michelle H. |last3=Theron |first3=Anne E. |last4=Joubert |first4=Annie M. |title=Antimitotic drugs in the treatment of cancer |journal=Cancer Chemotherapy and Pharmacology |date=2015 |volume=76 |issue=6 |pages=1101–1112 |doi=10.1007/s00280-015-2903-8 |pmid=26563258 |pmc=4648954 }}</ref> In collaborative study, he explored reversing [[multidrug resistance]] (MDR) in DOX-resistant human colorectal [[adenocarcinoma]] cells (Lo Vo/Dx) through long-term treatment with an equimolar mixture of three unmodified ODNs targeting adjacent sites on MDR1 [[mRNA]], delivered via the synthetic cationic lipid (DOTAP).<ref>{{cite journal |last1=Binkhathlan |first1=Ziyad |last2=Lavasanifar |first2=Afsaneh |title=P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives |journal=Current Cancer Drug Targets |date=2013 |volume=13 |issue=3 |pages=326–346 |doi=10.2174/15680096113139990076 |pmid=23369096 }}</ref> He also showed that a combination of antisense [[oligonucleotides]] could downregulate mdr-1 mRNA in the highly doxorubicin-resistant LoVo/Dx subline of human adenocarcinoma LoVo cells.<ref>{{Cite journal|title=Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance|first1=D.|last1=Byrne|first2=C.|last2=Daly|journal=Cytotechnology|volume=27|issue=1–3|page=122|date=1998|doi=10.1023/A:1008052401952 |pmid=19002787 |pmc=3449559 }}</ref> He went on to identify specific RNA-based targets in different cancers, including those implicated in colorectal cancer (CRC).<ref>{{Cite journal|title=Noncoding RNAs in cancer therapy resistance and targeted drug development|last1=Wang|first1=Wen-Tao|last2=Han|first2=Cai|last3=Sun|first3=Yu-Meng|last4=Chen|first4=Tian-Qi|last5=Chen|first5=Yue-Qin|journal=Journal of Hematology & Oncology|volume=12|issue=1|pages=5|date=2019|doi=10.1186/s13045-019-0748-z|pmid=31174564 |pmc=6556047 |doi-access=free }}</ref> He further highlighted the role of [[histone]] structure modification in causing cancer as well as its progression, while also asserting that histone [[methylation]] can lead to gene repression and activation, whereas [[acetylation]] is consistently linked with gene activation.<ref>{{cite journal |last1=Blondy |first1=Sabrina |last2=David |first2=Valentin |last3=Verdier |first3=Mireille |last4=Mathonnet |first4=Muriel |last5=Perraud |first5=Aurélie |last6=Christou |first6=Niki |title=5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes |journal=Cancer Science |date=2020 |volume=111 |issue=9 |pages=3142–3154 |doi=10.1111/cas.14532 |pmid=32536012 |pmc=7469786 }}</ref>

+

Mini, through his research, highlighted the negative role of P-glycoprotein (P-gp), an [[ABC transporter]] with extensive substrate specificity in anticancer therapy for leukemia and other solid tumors.<ref>{{Cite journal|last1=Vinogradov|first1=Serguei|last2=Wei|first2=Xin|title=Cancer stem cells and drug resistance: the potential of nanomedicine|journal=Nanomedicine (Lond)|volume=7|issue=4|date=2012|pages=597–615 |doi=10.2217/nnm.12.22|pmid=22471722|pmc=3376090}}</ref> He then modified anticancer drugs to reduce P-gp-mediated efflux<ref>{{Cite journal|title=Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment|first1=Deepali|last1=Waghray|first2=Qinghai|last2=Zhang|journal=Journal of Medicinal Chemistry|volume=61|issue=12|pages=5108–5121|date=2018|doi=10.1021/acs.jmedchem.7b01457|pmid=29251920 |pmc=6281405 }}</ref> and underlined the need for creating drugs that are non-P-gp substrates to counter cancer resistance hindrances.<ref>{{cite journal |last1=Van Vuuren |first1=Rustelle Janse |last2=Visagie |first2=Michelle H. |last3=Theron |first3=Anne E. |last4=Joubert |first4=Annie M. |title=Antimitotic drugs in the treatment of cancer |journal=Cancer Chemotherapy and Pharmacology |date=2015 |volume=76 |issue=6 |pages=1101–1112 |doi=10.1007/s00280-015-2903-8 |pmid=26563258 |pmc=4648954 }}</ref> In collaborative study, he explored reversing [[multidrug resistance]] (MDR) in the highly doxorubicin (Dx)-resistant human colorectal [[adenocarcinoma]] cell line(LoVo/Dx) through long-term treatment with an equimolar mixture of three unmodified antisense oligonucleotides (ODNs) targeting adjacent sites on MDR1 mRNA, delivered via the synthetic cationic lipid (DOTAP).<ref>{{cite journal |last1=Binkhathlan |first1=Ziyad |last2=Lavasanifar |first2=Afsaneh |title=P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives |journal=Current Cancer Drug Targets |date=2013 |volume=13 |issue=3 |pages=326–346 |doi=10.2174/15680096113139990076 |pmid=23369096 }}</ref> He showed that this combination could downregulate mdr-1 mRNA in the LoVo/Dx subline.<ref>{{Cite journal|title=Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance|first1=D.|last1=Byrne|first2=C.|last2=Daly|journal=Cytotechnology|volume=27|issue=1–3|page=122|date=1998|doi=10.1023/A:1008052401952 |pmid=19002787 |pmc=3449559 }}</ref>

−

In another line of research, Mini explored the potential of Au-based complexes for their use as metallodrugs in cancer.<ref>{{cite journal |last1=Hussaini |first1=Sunusi Y. |last2=Haque |first2=Rosenani A. |last3=Razali |first3=Mohd R. |title=Recent progress in silver(I)-, gold(I)/(III)- and palladium(II)-N-heterocyclic carbene complexes: A review towards biological perspectives |journal=Journal of Organometallic Chemistry |date=2019 |volume=882 |pages=96–111 |doi=10.1016/j.jorganchem.2019.01.003 }}</ref> He also highlighted Et<sub>3</sub>PAuI's demonstrated activity against platinum-resistant ovarian cancer cells, while exhibiting cross-resistance in ovarian cancer cells resistant to [[auranofin]]. He has been named in the [[Stanford University]]-[[Elsevier]]-developed World’s Top 2% Scientists List 2024 and 2025.<ref>{{cite web |title=Mini, Enrico |url=https://topresearcherslist.com/Home/Profile/1124029https://topresearcherslist.com/Home/Profile/1124029 |website=World's Top 2% Scientists |access-date=6 January 2026}}</ref><ref>{{cite journal |last1=Abdalbari |first1=Farah H. |last2=Telleria |first2=Carlos M. |title=The gold complex auranofin: New perspectives for cancer therapy |journal=Discover Oncology |date=2021 |volume=12 |issue=1 |article-number=42 |doi=10.1007/s12672-021-00439-0 |pmid=35201489 |pmc=8777575 }}</ref>

+

Mini also explored the potential of Au-based complexes for their use as metallodrugs in cancer.<ref>{{cite journal |last1=Hussaini |first1=Sunusi Y. |last2=Haque |first2=Rosenani A. |last3=Razali |first3=Mohd R. |title=Recent progress in silver(I)-, gold(I)/(III)- and palladium(II)-N-heterocyclic carbene complexes: A review towards biological perspectives |journal=Journal of Organometallic Chemistry |date=2019 |volume=882 |pages=96–111 |doi=10.1016/j.jorganchem.2019.01.003 }}</ref> He has been named in the [[Stanford University]]-[[Elsevier]]-developed World’s Top 2% Scientists List 2024 and 2025.<ref>{{cite web |title=Mini, Enrico |url=https://topresearcherslist.com/Home/Profile/1124029https://topresearcherslist.com/Home/Profile/1124029 |website=World's Top 2% Scientists |access-date=6 January 2026}}</ref><ref>{{cite journal |last1=Abdalbari |first1=Farah H. |last2=Telleria |first2=Carlos M. |title=The gold complex auranofin: New perspectives for cancer therapy |journal=Discover Oncology |date=2021 |volume=12 |issue=1 |article-number=42 |doi=10.1007/s12672-021-00439-0 |pmid=35201489 |pmc=8777575 }}</ref>

HRShami (talk) 09:24, 9 February 2026 (UTC)

Done ―Tosca-the-engineer (talk) 09:58, 19 April 2026 (UTC)